Zuranolone to face challenges in Japan’s MDD market despite demonstrating rapid onset of action:… EP News Bureau Oct 22, 2024 Shionogi's zuranolone faces hurdles in Japan's MDD market, balancing rapid efficacy against safety concerns and established…
FDA accepts NDA and grants priority review of Zuranolone from Sage Therapeutics, Biogen EP News Bureau Feb 7, 2023 Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder…
Sage-Biogen drug improves symptoms in postpartum depression study Reuters Jun 3, 2022 The drug, Zuranolone, also reduced depression severity as early as the third day of treatment compared with placebo in the study…
